Sigma Planning Corp Grows Stock Position in Cellebrite DI Ltd. $CLBT

Sigma Planning Corp raised its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 100.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,000 shares of the company’s stock after buying an additional 12,000 shares during the quarter. Sigma Planning Corp’s holdings in Cellebrite DI were worth $384,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Cellebrite DI in the first quarter worth approximately $60,939,000. Invesco Ltd. increased its position in Cellebrite DI by 122.1% during the first quarter. Invesco Ltd. now owns 3,296,079 shares of the company’s stock worth $64,043,000 after purchasing an additional 1,811,757 shares during the last quarter. Phoenix Financial Ltd. raised its stake in Cellebrite DI by 153.5% during the second quarter. Phoenix Financial Ltd. now owns 2,014,617 shares of the company’s stock worth $32,232,000 after purchasing an additional 1,219,958 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of Cellebrite DI in the 1st quarter valued at $22,428,000. Finally, Royal Bank of Canada grew its stake in shares of Cellebrite DI by 11,705.0% during the 1st quarter. Royal Bank of Canada now owns 824,226 shares of the company’s stock valued at $16,015,000 after buying an additional 817,244 shares during the period. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Stock Up 0.9%

NASDAQ CLBT opened at $15.40 on Monday. Cellebrite DI Ltd. has a fifty-two week low of $13.10 and a fifty-two week high of $26.30. The business has a 50 day moving average price of $17.76 and a two-hundred day moving average price of $16.75. The stock has a market cap of $3.69 billion, a PE ratio of -20.26, a P/E/G ratio of 3.16 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings data on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.01. The company had revenue of $113.28 million for the quarter, compared to analyst estimates of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The business’s quarterly revenue was up 18.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.10 earnings per share. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Sell-side analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CLBT has been the topic of a number of research reports. Needham & Company LLC cut their price objective on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, August 14th. Wall Street Zen lowered shares of Cellebrite DI from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday. Lake Street Capital dropped their price objective on shares of Cellebrite DI from $24.00 to $22.00 and set a “buy” rating for the company in a research report on Friday, August 15th. Finally, JPMorgan Chase & Co. raised their target price on shares of Cellebrite DI from $20.00 to $23.00 and gave the company an “overweight” rating in a research note on Wednesday, September 24th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, Cellebrite DI has an average rating of “Moderate Buy” and an average target price of $21.00.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.